Biotech Values

[DewDiligence]

ANTICOAGULANT INDEX

[Added PR on Lancet study and
updates on various drug candidates.]

General
#msg-25160571 Anticoagulant market has large potential (WSJ)
#msg-25985612 Anticoagulant market has large potential (graphic)
#msg-18759853 Overview of the new oral anticoagulants
#msg-26451612 Venous thromboembolism is a big, big problem (The Lancet)

M118
#msg-24457684 M118 has blockbuster potential
#msg-23604134 MNTA starts phase-2 in ACS
#msg-19617749 Start of phase-1 using sub-Q formulation
#msg-25147975 M118 vs oral FXa inhibitors

Rivaroxaban
#msg-25147464 Rivaroxaban bests Lovenox in VTE prevention
#msg-24337258 Bayer plans 50,000(!)-patient study

Apixaban
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2

Dabigatran
#msg-26086079 BI completes enrollment of huge AF trial
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention

Miscellaneous
#msg-26298260 Biotinylated Idraparinux causes excess bleeding in AF
#msg-22938795 Status of SNY’s SR123781, AVE5026, and Otamixaban
#msg-10569101 Arixtra bests Lovenox in ACS
#msg-26385806 NUVO’s NU172 starts phase-1